Health & Fitness
Thu, May 14, 2009Wed, May 13, 2009Tue, May 12, 2009Mon, May 11, 2009Fri, May 8, 2009Thu, May 7, 2009Thu, April 16, 2009Wed, April 15, 2009Tue, April 14, 2009Mon, April 13, 2009Fri, April 10, 2009Thu, April 9, 2009Wed, April 8, 2009Tue, April 7, 2009Mon, April 6, 2009Fri, April 3, 2009Thu, April 2, 2009Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Sun, March 15, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009CV Therapeutics, Inc.: CV Therapeutics Announces Presentations at the American College of Cardiology 58th Annual Scientific Ses
Published in Health and Fitness on Monday, March 16th 2009 at 14:04 GMT, Last Modified on 2009-03-16 14:05:44 by Market Wire
PALO ALTO, CA--(Marketwire - March 16, 2009) - CV Therapeutics, Inc. (
Poster Sessions
Increased CO2 Levels Augment Late Sodium Current and Cause Torsade de Pointes; Poster, Sunday, March 29, 9:30 a.m. EDT
Ranolazine, a Late Sodium Current Inhibitor, Markedly Reduces Ventricular Arrhythmias in a Model of Coronary Occlusion/Reperfusion; Poster, Sunday, March 29, 9:30 a.m. EDT
Ventricular Arrhythmias Following Non-ST Segment Elevation ACS and the Relationship with Sudden Cardiac Death in the MERLIN TIMI-36 Trial; Poster, Monday, March 30, 9:30 a.m. EDT
Blunting of the Heart Rate Response to Adenosine and Regadenoson in Relation to Hyperglycemia and the Metabolic Syndrome in the ADVNACE MPI Trials; Poster, Tuesday, March 31, 9:30 a.m. EDT
Additional information regarding the ACC 58th Annual Scientific Sessions can be accessed at [ http://acc09.acc.org/Pages/default.aspx ].
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.
CV Therapeutics' approved products in the United States include Ranexa® (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan® (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.
